# Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes

> **NCT00997243** · PHASE2 · TERMINATED · sponsor: **Alison Walker** · enrollment: 7 (actual)

## Conditions studied

- Leukemia
- Myelodysplastic Syndromes

## Interventions

- **BIOLOGICAL:** lintuzumab
- **DRUG:** 5-azacytidine

## Key facts

- **NCT ID:** NCT00997243
- **Lead sponsor:** Alison Walker
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-11
- **Primary completion:** 2010-09
- **Final completion:** 2011-05
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Drug no longer being supplied by sponsor
- **Last updated:** 2017-05-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00997243

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00997243, "Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00997243. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*